

3-(3-Bromophenyl)-1-phenylprop-2-en-1-one


Shea-Lin Ng,^a P. S. Patil,^b
Ibrahim Abdul Razak,^a
Hoong-Kun Fun^{a*} and
S. M. Dharmaprasanth^b^aX-ray Crystallography Unit, School of Physics,
Universiti Sains Malaysia, 11800 USM, Penang,
Malaysia, and ^bDepartment of Studies in
Physics, Mangalore University, Mangalagan-
gotri, Mangalore 574 199, India

Correspondence e-mail: hkfun@usm.my

Key indicators

Single-crystal X-ray study
T = 100 K
Mean $\sigma(\text{C}-\text{C}) = 0.002 \text{ \AA}$
R factor = 0.030
wR factor = 0.090
Data-to-parameter ratio = 47.7For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.The enone group and the benzene rings of the title compound, $\text{C}_{15}\text{H}_{11}\text{BrO}$, are each planar. The molecules are linked *via* C—H \cdots O interactions into wave-like chains along the *c* axis and the chains are stacked along the *b* axis.Received 25 January 2006
Accepted 30 January 2006

Comment

Chalcones show an impressive array of pharmacological activities, such as antiprotozoal (Nielsen *et al.*, 1998; Li *et al.*, 1995; Liu *et al.*, 2001), anti-inflammatory (Hsieh *et al.*, 1998), nitric oxide inhibition (Rojas *et al.*, 2002) and anticancer properties. Recently it has been noted that bromo-substituted derivatives of chalcones exhibit extremely high and fast non-linearity (Fichou *et al.*, 1988; Zhang *et al.*, 1990; Zhao *et al.*, 2000), and show preferences to crystallize as non-centrosymmetric structures. For this reason, they have been the objective of several experimental and theoretical studies, aimed mainly at the determination of their crystal structures (Sathiyamoorthi, Chinnakali, Nanjundan, Radhika *et al.*, 2005; Sathiyamoorthi, Chinnakali, Nanjundan, Santhi *et al.*, 2005; Sathiyamoorthi, Chinnakali, Nanjundan, Selvam *et al.*, 2005; Sathiyamoorthi, Chinnakali, Nanjundan, Unnithan *et al.*, 2005; Radha Krishna *et al.*, 2005; Uchida *et al.*, 1995). We report here the synthesis and crystal structure of the title compound, (I).The bond lengths and angles are within normal ranges (Allen *et al.*, 1987) and similar to those observed in other comparable structures (Jeyabharathi *et al.*, 2002; Patil *et al.*, 2006; Ravishankar *et al.*, 2005; Sathiyamoorthi, Chinnakali, Nanjundan, Radhika *et al.*, 2005; Sathiyamoorthi, Chinnakali, Nanjundan, Santhi *et al.*, 2005; Sathiyamoorthi, Chinnakali, Nanjundan, Selvam *et al.*, 2005; Sathiyamoorthi, Chinnakali, Nanjundan, Unnithan *et al.*, 2005; Teh *et al.*, 2006). The short H5 \cdots H8 (2.28 Å) contact causes the bond angle C9—C10—C11 [123.08 (9)°] to deviate significantly from 120°. In addition, the short H8 \cdots H11 (2.14 Å) contact results in a slight widening of the C5—C6—C7 angle to 122.58 (9)°.

The molecule of (I) (Fig. 1) is approximately planar. The enone group (O1/C7—C9) and the two benzene rings, C1—C6 and C10—C15, are each planar with largest deviations of 0.023 (1), 0.008 (1) and 0.008 (1) Å for atoms C9, C4 and C10,

respectively. The enone group makes dihedral angles of 13.59 (6) and 12.22 (6)° with the C1–C6 and C10–C15 benzene rings, respectively. The dihedral angle between the two benzene rings is 3.95 (4)°.

In the crystal structure, atom O1 is involved in both intra- and intermolecular hydrogen bonds. Intermolecular C5–H5···O1ⁱ (symmetry code as in Table 1) interactions link the molecules into wave-like chains along the *c* axis. The chains are stacked along the *b* axis. The intramolecular C7–H7···O1 interaction generates an *S*(5) ring motif (Bernstein *et al.*, 1995).

Experimental

Compound (I) was obtained by the condensation of 3-bromobenzaldehyde (0.01 mol) and acetophenone (0.01 mol) in ethanol (60 ml) in the presence of NaOH (2 ml, 30%). After stirring for 2 h, the contents of the flask were poured into ice-cold water and allowed to stand for 24 h. The resulting crude solid compound was collected by filtration, dried and recrystallized twice from acetone. Crystals suitable for X-ray diffraction study were grown by slow evaporation of an acetone solution over a period of 10 d.

Crystal data

C ₁₅ H ₁₁ BrO	<i>D</i> _x = 1.602 Mg m ⁻³
<i>M</i> _r = 287.15	Mo Kα radiation
Monoclinic, <i>P</i> 2 ₁ / <i>c</i>	Cell parameters from 6943 reflections
<i>a</i> = 14.3238 (2) Å	<i>θ</i> = 1.5–40.0°
<i>b</i> = 7.4913 (1) Å	<i>μ</i> = 3.43 mm ⁻¹
<i>c</i> = 11.2786 (2) Å	<i>T</i> = 100.0 (1) K
<i>β</i> = 100.325 (1)°	Block, colourless
<i>V</i> = 1190.64 (3) Å ³	0.75 × 0.33 × 0.30 mm
<i>Z</i> = 4	

Data collection

Bruker SMART APEX2 CCD area-detector diffractometer	7339 independent reflections
<i>ω</i> scans	5499 reflections with <i>I</i> > 2σ(<i>I</i>)
Absorption correction: multi-scan (SADABS; Bruker, 2005)	<i>R</i> _{int} = 0.035
<i>T</i> _{min} = 0.065, <i>T</i> _{max} = 0.357	<i>θ</i> _{max} = 40.0°
48289 measured reflections	<i>h</i> = −25 → 25
	<i>k</i> = −13 → 13
	<i>l</i> = −20 → 20

Refinement

Refinement on <i>F</i> ²	$w = 1/[\sigma^2(F_o^2) + (0.0447P)^2 + 0.2439P]$
$R[F^2 > 2\sigma(F^2)] = 0.030$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.090$	(Δ/σ) _{max} = 0.001
<i>S</i> = 1.10	$\Delta\rho_{max} = 0.71 \text{ e } \text{Å}^{-3}$
7339 reflections	$\Delta\rho_{min} = -0.74 \text{ e } \text{Å}^{-3}$
154 parameters	
H-atom parameters constrained	

Table 1

Hydrogen-bond geometry (Å, °).

<i>D</i> –H··· <i>A</i>	<i>D</i> –H	H··· <i>A</i>	<i>D</i> ··· <i>A</i>	<i>D</i> –H··· <i>A</i>
C7–H7···O1	0.93	2.45	2.7909 (15)	102
C5–H5···O1 ⁱ	0.93	2.50	3.4106 (15)	166

Symmetry code: (i) *x*, −*y* + ½, *z* + ½.

H atoms were placed in calculated positions, with a C–H distance of 0.93 Å. The *U*_{iso}(H) values were constrained to be 1.2*U*_{eq}(C).




Figure 1
The structure of (I), showing 50% probability displacement ellipsoids and the atomic numbering. The dashed line indicates a hydrogen bond.




Figure 2
The crystal packing of (I), viewed approximately down the *a* axis. Hydrogen bonds are shown as dashed lines.

Data collection: APEX2 (Bruker, 2005); cell refinement: APEX2; data reduction: SAINT (Bruker, 2005); program(s) used to solve structure: SHELXTL (Sheldrick, 1998); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL, PARST (Nardelli, 1995) and PLATON (Spek, 2003).

The authors thank the Malaysian Government and Universiti Sains Malaysia for the Scientific Advancement Grant Allocation (SAGA) grant No. 304/PFIZIK/653003/A118 and the short-term grant No. 304/PFIZIK/635028.

References

- Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). *J. Chem. Soc. Perkin Trans. 2*, pp. S1–19.
- Bernstein, J., Davis, R. E., Shimoni, L. & Chang, N.-L. (1995). *Angew. Chem. Int. Ed. Engl.* **34**, 1555–1573.
- Bruker (2005). APEX2 (Version 1.27), SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
- Fichou, D., Watanabe, T., Takeda, T., Miyata, S., Goto, Y. & Nakayama, M. (1988). *Jpn J. Appl. Phys.* **27**, L429–L430.
- Hsieh, H. K., Lee, T. H., Wang, J. P., Wang, J. J. & Lin, C. N. (1998). *Pharm. Res.* **15**, 39–46.
- Jeyabharathi, A., Ponnuswamy, M. N., Nanjundan, S., Fun, H. K., Chantrapromma, S., Usman, A. & Razak, I. A. (2002). *Acta Cryst.* **C58**, o26–o28.
- Li, R., Kenyon, G. L., Cohen, F. E., Chem, X., Gong, B., Dominguez, J. N., Davidson, E., Kurzban, G., Miller, R. E., Nuzum, E. O., Rosenthal, P. J. & McKerrow, J. H. (1995). *J. Med. Chem.* **38**, 5031–5037.
- Liu, M., Wilairat, P. & Go, M. L. (2001). *J. Med. Chem.* **44**, 4443–4452.

- Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
- Nielsen, S. F., Christensen, S. B., Cruciani, G., Kharazmi, A. & Liljefors, T. (1998). *J. Med. Chem.* **41**, 4819–4832.
- Patil, P. S., Teh, J. B. J., Fun, H.-K., Razak, I. A. & Dharmaparakash, S. M. (2006). *Acta Cryst.* **E62**, o896–o898.
- Radha Krishna, J., Kumar, N. J., Krishnaiah, M., Rao, C. V., Rao, K. & Puranic, V. G. (2005). *Acta Cryst.* **E61**, o1323–o1325.
- Ravishankar, T., Chinnakali, K., Nanjundan, S. Selvam, P., Fun, H.-K. & Yu, X.-L. (2005). *Acta Cryst.* **E61**, o405–o407.
- Rojas, J., Paya, M., Dominguez, J. N. & Ferrandiz, M. L. (2002). *Bioorg. Med. Chem. Lett.* **12**, 1951–1954.
- Sathiya Moorthi, S., Chinnakali, K., Nanjundan, S., Radhika, R., Fun, H.-K. & Yu, X.-L. (2005). *Acta Cryst.* **E61**, o480–o482.
- Sathiya Moorthi, S., Chinnakali, K., Nanjundan, S., Santhi, R. & Fun, H.-K. (2005). *Acta Cryst.* **E61**, o3514–o3516.
- Sathiya Moorthi, S., Chinnakali, K., Nanjundan, S., Selvam, P., Fun, H.-K. & Yu, X.-L. (2005). *Acta Cryst.* **E61**, o743–o745.
- Sathiya Moorthi, S., Chinnakali, K., Nanjundan, S., Unnithan, C. S., Fun, H.-K. & Yu, X.-L. (2005). *Acta Cryst.* **E61**, o483–o485.
- Sheldrick, G. M. (1998). *SHELXTL*. Version 5.1. Bruker AXS Inc., Madison, Wisconsin, USA.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Teh, J. B. J., Patil, P. S., Fun, H.-K., Razak, I. A. & Dharmaparakash, S. M. (2006). *Acta Cryst.* **E62**, o890–o892.
- Uchida, T., Kozawa, K., Kimura, Y. & Goto, Y. (1995). *Synth. Met.* **71**, 1705–1706.
- Zhang, G., Kinoshita, T., Sasaki, K., Goto, Y. & Nakayam, M. (1990). *J. Cryst. Growth*, **100**, 411–416.
- Zhao, B., Lu, W.-Q., Zhou, Z.-H. & Wu, Y. (2000). *J. Mater. Chem.* **10**, 1513–1517.